Ono-AE1-329

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Ono-AE1-329
• 英文别名: 2-[3-[(1R,2S,3R)-3-hydroxy-2-[(E,3S)-3-hydroxy-5-[2-(methoxymethyl)phenyl]pent-1-enyl]-5-oxocyclopentyl]sulfanylpropylsulfanyl]acetic acid
• 化学式: C₂₃H₃₂O₆S₂
• 分子量: 468.6
• InChiKey: BVGVPUMSPSNRRQ-CNOJNPITSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  31
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  155
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• METHODS TO ENHANCE DELIVERY AND ENGRAFTMENT OF STEM CELLS INCLUDING THE IDENTIFICATION OF SPECIFIC PROSTAGANDIN E2 RECEPTORS
  申请人：Indiana University Research & Technology Corporation

  公开号：EP2499242B1

  公开（公告）日：2019-05-01
• HEMATOPOIETIC STEM AND PROGENITOR CELL THERAPY
  申请人：Shoemaker Daniel

  公开号：US20140030232A1

  公开（公告）日：2014-01-30

  The invention provides improved methods for cell therapy. In particular, the invention provides therapeutic compositions of modified hematopoietic stem and/or progenitor cells having improved engraftment and homing properties, and methods of making the therapeutic composition. The invention further provides methods of improving the efficacy of hematopoietic stem and progenitor cell transplantation including transplanting the therapeutic composition to subjects in need of hematopoietic system reconstitution.
• METHODS OF TREATING ISCHEMIA
  申请人：FATE THERAPEUTICS, INC.

  公开号：US20140348802A1

  公开（公告）日：2014-11-27

  The invention provides compositions comprising stem and/or progenitor cells that have been treated to enhance the therapeutic properties of the cells for treating ischemia. In particular, the present invention relates to the use of stem and/or progenitor cells having enhanced therapeutic properties to treat an ischemic tissue, a tissue damaged by ischemia, or at least one symptom associated with an ischemic tissue or a tissue damaged by ischemia.
• STEM CELL CULTURE MEDIA AND METHODS OF ENHANCING CELL SURVIVIAL
  申请人：FATE THERAPEUTICS, INC.

  公开号：US20150044176A1

  公开（公告）日：2015-02-12

  The invention provides improved methods for preparing hematopoietic cells for transplantation and the resulting improved hematopoietic cell compositions. The invention further relates to improved culture media and methods of culturing, processing, modulating, and expanding blood cell products for hematopoietic transplantation.
• MODULATION OF T LYMPHOCYTES
  申请人：Fate Therapeutics, Inc.

  公开号：US20190119635A1

  公开（公告）日：2019-04-25

  The present disclosure relates to molecular biology, cell biology and immunology. Specifically, the present disclosure provides compositions and methods for modulating an isolated population of T lymphocytes to improve the therapeutic potential thereof.